Lumos Pharma Inc

Lumos Pharma — NewLink Genetics — Merger or Acquisition (September 2019)

22 slides from Lumos Pharma's merger presentation, Sep 30, 2019

  1. Slide 1: NewLink Genetics and Lumos Pharma Merger

    NEWLINK GENETICS and LUMOS PHARMA MERGER Focused on Developing Therapies to Treat Rare Diseases September 30, 2019

  2. Slide 2: Legal Disclaimer

    LEGAL DISCLAIMER Additional Information and Where to Find It In connection with the proposed transaction, NewLink Genetics Corporation (“NewLink”) will be filing documents with the SEC, including preliminary and definitive proxy statements relating to the proposed transaction. The definitive proxy s

  3. Slide 3: Forward-Looking Statements

    FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements of NewLink that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements, within the meaning of The Private Se

  4. Slide 4: We are focused on the extraordinary

    We are focused on the extraordinary Our goal is to bring novel therapies to people with rare diseases. 4

  5. Slide 5: Management Welcome

    MANAGEMENT WELCOME Experienced management team with significant clinical development and commercial experience Richard Hawkins – CEO of Lumos Pharma, developer of growth hormone (GH) agonists for use in acromegaly at Sensus (sold to Pfizer). Built one of the first contract recombinant protein manufa

  6. Slide 6: Transaction Summary

    TRANSACTION SUMMARY Post merger, NewLink Genetics and Lumos Pharma stockholders are each expected to own approximately 50% of the combined company. The combined company will effect a reverse stock split. NewLink Genetics is expected to be renamed “Lumos Pharma, Inc.” and to trade on the Nasdaq under

  7. Slide 7: Significant High-Quality Investors

    SIGNIFICANT HIGH-QUALITY INVESTORS Lumos Pharma brings to the merger strong, well-recognized healthcare investors  Well-known healthcare venture investors: NEA and Santé Ventures  Large healthcare investors that participate in public and private markets: Deerfield Management and a fund managed by

  8. Slide 8: Post-Merger Strategic Priorities

    POST-MERGER STRATEGIC PRIORITIES Initial focus will be on initiation of Phase 2b trial of LUM-201 (ibutamoren) for pediatric growth hormone deficiency (PGHD) Build pipeline through strategic acquisitions of assets focusing on rare diseases LUM-201: Oral secretagogue candidate for PGHD  Established

  9. Slide 9: LUM-201 Program Pipeline

    LUM-201 PROGRAM PIPELINE Product Candidate Orphan Indication Preclinical Phase I Phase II Phase III Status Pediatric Growth Phase 2b – expected to Hormone Deficiency initiate mid-2020 (PGHD) Ibutamoren Ongoing clinical planning (LUM-201) Turner Syndrome for Phase 2 trial, timing dependent on PGHD da

  10. Slide 10: PGHD and Standard of Care

    PGHD AND STANDARD OF CARE  PGHD occurs due to inadequate secretion of growth hormone by the pituitary gland during childhood  PGHD can be either hereditary or acquired, although the majority of cases have unknown causes (idiopathic)  Lack of physical growth is the most obvious manifestation; but

  11. Slide 11: Pediatric Growth Hormone Deficiency Market Analysis

    PEDIATRIC GROWTH HORMONE DEFICIENCY MARKET ANALYSIS Global rhGH sales for pediatric Global Sales Distribution patients with growth hormone of rhGH for PGHD in 2016 in deficiency (PGHD) reached $1.12 the major markets1 Billion in 2016 in major markets1 Japan ► Expected CAGR for global PGHD 20.6% sale

  12. Slide 12: Established Value Proposition and Regulatory Path

    ESTABLISHED VALUE PROPOSITION AND REGULATORY PATH Vision Targeted Patients Near-term Clinical Milestone LUM-201, if approved, has the Predictive enrichment markers (PEM) are Phase 2b trial planned for mid- potential to become the world’s first planned to be employed to optimize the 2020. oral growth

  13. Slide 13: LUM-201: Mechanism of Action

    LUM-201: MECHANISM OF ACTION GHSR1a Hypothalamus LUM 201  Oral LUM-201 is a growth hormone (GH) SST GHRH secretagogue GHSR1a  Acts as an agonist of GH Pituitary Secretagogue Receptor (GHSR1a) to stimulate GH release1 GH  LUM-201 has been observed to increase the amplitude of endogenous pulsatile

  14. Slide 14: Targeted PGHD Population

    TARGETED PGHD POPULATION PEM-Positive: Included PEM-Negative: Excluded GHSR1a GHSR1a Hypothalamus Hypothalamus LUM SST GHRH SST GHRH LUM 201 201 GHSR1a GHSR1a Pituitary Pituitary GH GH IGF-1 Functional but reduced HP-GH axis Non-functional HP-GH axis • Able to secrete some, but insufficient, GH • Un

  15. Slide 15: Post-Hoc: Predictive Enrichment Markers at Work

    POST-HOC: PREDICTIVE ENRICHMENT MARKERS AT WORK All Subjects PEM-Positive  Naïve PGHD patients, 020 trial 16 16  Data from first 6 months prior to ) ) r r y y 1 / / p=0.082 formulation change m m c c ( 12 ( 12 y Absolute y t t i i c c  LUM-201 0.8 mg/kg not o o l l e e V Growth V statistically di

  16. Slide 16: Prior Clinical Experience in PGHD with LUM-201

    PRIOR CLINICAL EXPERIENCE IN PGHD WITH LUM-201  Prior PGHD trials  Conducted prior to Lumos acquisition of LUM-201 in July 2018  3 clinical trials in pediatric population explored safety and efficacy  Phase 1 Trial 019 – PK, Phase 2 Trial 020 – Naïve, Phase 2 Trial 024 – Previously rhGH treated

  17. Slide 17: Clinical Development Outline for PGHD

    CLINICAL DEVELOPMENT OUTLINE FOR PGHD ► Proposed Phase 2b PGHD clinical trial design ► PEM-enabled patient selection ► Three dose levels of LUM-201 (0.8, 1.6, 3.2 mg/kg) ► Positive control arm of daily rhGH injections ► 6-month dosing ► 20 subjects per arm ► Treatment-naïve, age-matched cohorts ► Ex

  18. Slide 18: LUM-201: Other Potential Rare Endocrine Disorders

    LUM-201: OTHER POTENTIAL RARE ENDOCRINE DISORDERS Prader-Willi Syndrome Small for Gestational Age rhGH FDA approved in rhGH FDA approved in Beyond PGHD, Lumos 2000 2001 also plans to investigate LUM-201 for other rare endocrine disorders, for which rhGH has been approved Idiopathic Short Stature Tur

  19. Slide 19: Orphan Designation and IP

    ag ORPHAN DESIGNATION AND IP ► Orphan Drug Designation received in US and EU for GHD in 2017 ► With potential pediatric extensions, eligible for 12 years exclusivity in EU and 7.5 years in US. ► Plan to seek designation in Japan ► Intellectual Property ► “Detecting and Treating Growth Hormone Defici

  20. Slide 20: LUM-201 Summary

    LUM-201 SUMMARY If approved, potential to be the first oral growth hormone secretagogue therapy for PGHD  Established regulatory path – Phase 2b in PGHD anticipated to start mid-2020  Clinical data supports target engagement and safety  ~ 1,200 subjects dosed including ~150 PGHD patients  Predic

  21. Slide 21: Secure Pro Forma Cash Position

    SECURE PRO FORMA CASH POSITION ► Combined pro forma cash balance at year-end 2019 projected to be ~ $80M, excluding costs to right-size the combined organization ► Spending after merger expected to be an average of $6.5-$7.5M per quarter in 2020, excluding restructuring charges and severance costs ►

  22. Slide 22: Merger offers opportunity to develop rare disease therapeutics

     Merger offers opportunity to develop therapeutics for the rare disease community  LUM-201: Potential to improve upon treatment paradigm in established and sizeable market  Strong balance sheet and streamlined operations expected to provide substantial runway  Management team with deep Lumos Pha

NewLink Genetics — Merger or Acquisition (September 2019) on 6ix